Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?

Lung cancer patients ≥75 years represent nearly 40% of all lung cancer patients and continue to increase. If elderly patients have a good performance status and adequate organ function, they can be treated the same as non-elderly patients. However, few comparative studies limited to elderly patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Takigawa, Nagio, Ochi, Nobuaki, Nakagawa, Nozomu, Nagasaki, Yasunari, Taoka, Masataka, Ichiyama, Naruhiko, Mimura, Ayaka, Nakanishi, Hidekazu, Kohara, Hiroyuki, Yamane, Hiromichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409336/
https://www.ncbi.nlm.nih.gov/pubmed/32708291
http://dx.doi.org/10.3390/cancers12071995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409336/
https://www.ncbi.nlm.nih.gov/pubmed/32708291
http://dx.doi.org/10.3390/cancers12071995

Ejemplares similares